Document is current
Any future updates will be listed below
-
Authors
Borgen, Tove T. https://orcid.org/0000-0002-5012-0903
Brunborg, Cathrine https://orcid.org/0000-0001-9050-2968
Frihagen, Frede https://orcid.org/0000-0002-4811-669X
Solberg, Lene B. https://orcid.org/0000-0002-8705-5033
Andreasen, Camilla https://orcid.org/0000-0002-8005-6869
Figved, Wender https://orcid.org/0000-0002-8201-9818
Apalset, Ellen M. https://orcid.org/0000-0003-3821-8008
Gjertsen, Jan-Erik https://orcid.org/0000-0002-8490-268X
Basso, Trude https://orcid.org/0000-0001-8045-2610
Stutzer, Jens-Meinhard https://orcid.org/0000-0003-3512-2414
Nordsletten, Lars https://orcid.org/0000-0003-4642-5787
Eriksen, Erik F. https://orcid.org/0000-0002-5945-722X
Bjørnerem, Åshild https://orcid.org/0000-0002-3123-2950
-
Funding
Funding for this research was provided by:
Norges Forskningsråd (243852)
Helse Nord RHF (14083)
Vestre Viken (1903007)
Vestre Viken Hospital Trust
- License Information
-
More Information
Article History
Received: 24 August 2024
Accepted: 22 February 2025
First Online: 2 August 2025
Declarations
:
: Cathrine Brunborg, Camilla Andreasen, Ellen M. Apalset, Trude Basso, and Åshild Bjørnerem declare that they have no conflict of interest. Tove T. Borgen has received speaker’s fee from Amgen, UCB, Pharma Prim, and Roche Diagnostics. Frede Frihagen has received speaker fees from UCB and Amgen. Lene B. Solberg has received speaker’s fee from Eli Lilly, Amgen, and UCB. Wender Figved has received speaker fees from Ortomedic AS and Zimmer Biomet. Jan-Erik Gjertsen has received speaker fees from Ortomedic AS, Heraeus Medical, Smith and Nephew, and LINK Norway. Jens-Meinhard Stutzer has received speaker fees from BSN Medical. Lars Nordsletten has received speaker fees from Novartis, Eli Lilly, and Ortomedic AS. Erik F. Eriksen has received speaker fees from Novartis, Eli Lilly, Amgen, MSD, EffRx, IDS, and Shire.
